Impaired Adiponectin Signaling Contributes to Disturbed Catabolism of Branched-Chain Amino Acids in Diabetic Mouse

  1. Ling Tao1,*
  1. 1Department of Cardiology, Xijing Hospital, The Fourth Military Medical University, 15 Changlexi Road, Xi’an, 710032, China;
  2. 2Experiment Teaching Center, The Fourth Military Medical University, 169 Changlexi Road, Xi’an, 710032, China;
  3. 3Department of Anesthesiology, Xijing Hospital, The Fourth Military Medical University, 15 Changlexi Road, Xi’an, 710032, China;
  4. 4Department of Cardiology, The 306th Hospital of PLA, 9 Anxiangbeili Street, Beijing, 100101, China.
  1. *Corresponding Authors: Ling Tao, E-mail: lingtao2006{at}gmail.com

Abstract

The branched-chain amino acids (BCAA) accumulated in type 2 diabetes mellitus are independent contributors to insulin resistance. The activity of branched-chain α-keto acid dehydrogenase (BCKD) complex, rate-limiting enzyme in BCAA catabolism, is reduced in diabetic states, which contributes to elevated BCAA concentrations. However, the mechanisms underlying decreased BCKD activity remain poorly understood. Here we demonstrate that mitochondrial phosphatase 2C (PP2Cm), a newly identified BCKD phosphatase which increases BCKD activity, was significantly down-regulated in ob/ob and type 2 diabetic mice. Interestingly, in adiponectin knockout (APN-/-) mice fed with high-fat-diet (HD), PP2Cm expression and BCKD activity were significantly decreased, whereas BCKD kinase (BDK) which inhibits BCKD activity was markedly increased. Concurrently, plasma BCAA and branched-chain α-keto acids (BCKA) were significantly elevated. APN treatment markedly reverted PP2Cm, BDK, BCKD activity, BCAA and BCKA levels in HD-fed APN-/- and diabetic animals. Additionally, increased BCKD activity caused by APN administration was partially but significantly inhibited in PP2Cm knockout mice. Finally, APN-mediated up-regulation of PP2Cm expression and BCKD activity were abolished when adenosine monophosphate-activated protein kinase (AMPK) was inhibited. Collectively, we have provided the first direct evidence that APN is a novel regulator of PP2Cm and systematic BCAA levels, suggesting that targeting APN may be a pharmacological approach to ameliorating BCAA catabolism in the diabetic state.

  • Received February 22, 2014.
  • Accepted July 9, 2014.
No Related Web Pages